Conversion Therapy to Everolimus in Renal Transplant Recipients: Results After One Year

Transplantation Proceedings

Volumn 40, Issue 3, 2008, Pages 711-713

  Giron, F ^a   Baez, Y ^a   Nino Murcia A ^a   Rodriguez J ^a   Salcedo, S ^a  

^a Department of Transplantation ^*  (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CADAVER; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 42949133484     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.012     Document Type: Article

References (10)

1. J. Pascual I.N. Boletis J.M. Campistol Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions Transplant Rev 20 2006 1
2. C. Dunn K.F. Croom Everolimus A review of its use in renal and cardiac transplantation Drugs 66 2006 547
3. E. Pohanka Conversion to everolimus in maintenance patients-current clinical strategies Nephrol Dial Transplant 21 Suppl 3 2006 iii24
4. S. Hariharan C.P. Johnson B.A. Bresnahan Improved graft survival after renal transplantation in the United States, 1998 to 96 N Engl J Med 342 2000 605
5. J. Morales A. Fierro D. Benavente Conversion from a calcineurin-inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria Transplant Proc 39 2007 591
6. S. Vitko H. Tedesco J. Eris Everolimus withh optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626
7. A.C. Webster V.W. Lee J.R. Chapman Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials Transplantation 81 2006 1234
8. H.H. Neumayer Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical development Transplantation 79 2005 S72
9. F.P. Schena R.K. Wali M.D. Pascoe The Sirolimus Renal Conversion Trial Study Group: A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients Am J Transplant 5 Suppl 11 2005 A1008
10. A.V. Mulay N. Hussain D. Fergusson Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials Am J Transplant 5 2005 1748